Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

105.38 -1.49 (-1.39%)
Official Closing Price Updated: 7:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,784,969
Open 106.21
Bid (Size) 105.00 (1)
Ask (Size) 105.59 (1)
Prev. Close 106.87
Today's Range 105.11 - 106.68
52wk Range 72.88 - 115.49
Shares Outstanding 2,531,374,696
Dividend Yield 2.47%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed. 
Via Benzinga
Will This Billion-Dollar Acquisition Be a Smart Move for Merck?
Merck recently completed its acquisition of a California-based biotech company. 
Via The Motley Fool

Performance

YTD
-5.18%
-5.18%
1 Month
-5.02%
-5.02%
3 Month
+4.13%
+4.13%
6 Month
+19.03%
+19.03%
1 Year
+29.33%
+29.33%

More News

Read More
Where Merck & Co Stands With Analysts
Via Benzinga
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
The 3 Best Biotech Stocks Under $1 to Buy for January
Via InvestorPlace
2 Market-Beating Stocks to Buy in 2023 and Hold for 10 Years
Via The Motley Fool
Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO (fluralaner) Chews for Dogs
From Merck & Co., Inc.
Via Business Wire
How I'd Invest $50,000 for Retirement If I Had to Start From Scratch
Via The Motley Fool
Earn Dividends Every Month With These 3 Stocks
Via The Motley Fool
My Biggest Winners Of 2022
Via Talk Markets
Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Futility
From Merck & Co., Inc.
Via Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy in First-Line Advanced or Unresectable Biliary Tract Cancer in KEYNOTE-966 Trial
From Merck & Co., Inc.
Via Business Wire
Want to Collect a Dividend Every Month? Buy These 3 High-Yielding Stocks
Via The Motley Fool
Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Via MarketBeat
Merck Announces Second-Quarter 2023 Dividend
From Merck & Co., Inc.
Via Business Wire
This Dow Jones Stock Crushed the Market in 2022 -- Can It Do It Again?
Via The Motley Fool
Seagen's Tukysa Becomes First FDA-Approved Treatment For HER2-Positive Metastatic Colorectal Cancer
Via Benzinga
Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects
Via Benzinga
Can Cannabinoid CB2 Receptor Antagonist Combined With KEYTRUDA Be Effective In Patients With Advanced Solid Tumors? These Two Companies Aim To Find Out
Via Benzinga
J.P.Morgan Healthcare Conference JPM23: Biotech Rally Favors Smaller Caps
Via Talk Markets
Novocure Has Fallen More Than 20% Over Seven Days — Why It Fell From Grace
Via Investor's Business Daily
3 Top Stocks to Buy for the Long Haul
Via The Motley Fool
Johnson & Johnson Cuts Production, Ends Contracts For Not So Successful COVID-19 Shot
Via Benzinga
FAA Technology Glitch Hits US Flights Operations, Coca-Cola & PepsiCo Under FTC Probe, Rivian Hit By Mass Executive Exodus: Today's Top Stories
Via Benzinga
Merck, Pfizer Rebuts China's Request For Further Price Cuts For COVID-19 Drugs
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.